Access to anti-retroviral drugs, male in Namibia

Namibia: Access to anti-retroviral drugs, male was 90.0% in 2024. ◆ Volatile

Latest (2024)
90.0%
Change on year
up 3.4%
World rank
13th
of 141 countries
All-time high
90.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Namibia, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 3 %2005: 7 %2006: 14 %2007: 23 %2008: 29 %2009: 32 %2010: 37 %2011: 44 %2012: 47 %2013: 52 %2014: 51 %2015: 60 %2016: 53 %2017: 63 %2018: 68 %2019: 75 %2020: 78 %2021: 81 %2022: 83 %2023: 87 %2024: 90 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Namibia stood at 90.0%. That is the highest value across all 25 years on record.

That represents a change of up 3.4% on the previous year and up 76.5% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Namibia peaked at 90.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Namibia 13th out of 141 countries with data for 2024, putting it in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Namibia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Namibia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 3.0%
2005 7.0% +133.3%
2006 14.0% +100.0%
2007 23.0% +64.3%
2008 29.0% +26.1%
2009 32.0% +10.3%
2010 37.0% +15.6%
2011 44.0% +18.9%
2012 47.0% +6.8%
2013 52.0% +10.6%
2014 51.0% -1.9%
2015 60.0% +17.6%
2016 53.0% -11.7%
2017 63.0% +18.9%
2018 68.0% +7.9%
2019 75.0% +10.3%
2020 78.0% +4.0%
2021 81.0% +3.8%
2022 83.0% +2.5%
2023 87.0% +4.8%
2024 90.0% +3.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 10.8% 0.0% 32.0% 10
2010s 55.0% 37.0% 75.0% 10
2020s 83.8% 78.0% 90.0% 5

Countries ranked near Namibia

  1. 11 Botswana 92.0% compare
  2. 12 Spain 91.0% compare
  3. 13 Burundi 90.0% compare
  4. 13 Malawi 90.0% compare
  5. 13 Switzerland 90.0% compare

See the full ranking of 160 places →

More gender data for Namibia

All data for Namibia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Namibia?
Access to anti-retroviral drugs, male in Namibia was 90.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Namibia?
The highest recorded value was 90.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Namibia?
The lowest recorded value was 0.0% in 2000.
How does Namibia rank for access to anti-retroviral drugs, male?
Namibia ranks 13th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Namibia?
Over the last ten years it is up 76.5%. The long-run trend across the full record is volatile.
Where does this Namibia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Namibia. Statizoid, drawing on UNAIDS estimates. Retrieved 05 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/namibia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/namibia/">Access to anti-retroviral drugs, male in Namibia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.